Reactogenicity and Immunogenicity Profiles of a Novel Pentavalent Diphtheria-Tetanus???Whole Cell Pertussis???Hepatitis B and Haemophilus Influenzae Type B Vaccine
- 1 August 2006
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 25 (8) , 706-712
- https://doi.org/10.1097/01.inf.0000223488.80814.df
Abstract
Combined vaccines containing diphtheria-tetanus-pertussis whole-cell (DTPw), Haemophilus influenzae type b (Hib), and hepatitis-B vaccines are essential for the continuing success of vaccination programs in developing nations. This randomized, dose-ranging study assessed the immunogenicity and reactogenicity of primary and booster vaccination with pentavalent DTPw-HBV/Hib vaccines containing 10, 5 or 2.5 microg of polyribosylribitol phosphate (PRP) conjugated to tetanus toxoid (trials Hib-052/064). Six hundred eighty infants were randomized to receive one of 5 vaccine combinations at 6, 10, and 14 weeks of age. Of these, 351 received the same vaccine at 15-24 months of age. The immune response was evaluated on blood samples collected 1 month after the 3-dose primary course and before and 6 weeks after the booster dose. Reactogenicity was assessed during a 4-day period after each vaccine dose using diary cards. After primary vaccination, all subjects had seroprotective anti-PRP antibody concentrations (> or = 0.15 microg/mL) and > 95% had concentrations > or = 1.0 microg/mL, irrespective of the PRP dose administered. Anti-PRP antibody avidity after primary vaccination and antibody persistence until the second year of life were similar among groups. The booster dose induced marked increases in anti-PRP antibody GMCs and antibody avidity, indicative of effective priming and the presence of immune memory. All vaccination regimens elicited good immune responses and comparable antibody persistence to the other vaccine antigens, with significant increases in all antibody concentrations observed after boosting. All vaccination regimens were safe, with similar overall reactogenicity profiles. Hib conjugate vaccines containing reduced amounts of PRP can be effectively combined with the licensed DTPw-HBV vaccine to provide protection against 5 major childhood pathogens in a single injection.Keywords
This publication has 21 references indexed in Scilit:
- Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem™) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugateVaccine, 2005
- Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccinesVaccine, 2004
- Global reduction of Hib disease: what are the next steps? Proceedings of the meetingThe Journal of Pediatrics, 2003
- Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infantsThe Pediatric Infectious Disease Journal, 2002
- Functional Antibody Activity Elicited by Fractional Doses ofHaemophilus influenzaeType b Conjugate Vaccine (Polyribosylribitol Phosphate–Tetanus Toxoid Conjugate)Clinical and Diagnostic Laboratory Immunology, 2001
- The Risk of Seizures after Receipt of Whole-Cell Pertussis or Measles, Mumps, and Rubella VaccineNew England Journal of Medicine, 2001
- Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children Primed in Infancy With Acellular VaccinesPediatrics, 2001
- The Gambian Haemophilus influenzae type b vaccine trial: what does it tell us about the burden of Haemophilus influenzae type b disease?The Pediatric Infectious Disease Journal, 1998
- Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of lifeVaccine, 1996
- Haemophilus influenzae Type b Conjugate and Combination VaccinesClinical Immunotherapeutics, 1995